I bought glove before the pandemic strike and now I bought Genting & Genm before the business recover. I buy in advance and I get cheap entry. If I buy when the business is recovering than the entry price would be way too high. That's my strategy of investment.

Stocks fell Thursday, with the Dow and S&P 500 adding to Wednesday’s losses, as optimism over a COVID-19 vaccine gave way to fear that rising coronavirus infections will derail a still evolving recovery.

[Click here to read what’s moving markets heading into Friday, Nov. 13]

The pandemic has tightened its grip on the world’s largest economy, with new COVID-19 cases hitting a record of more than152,000 on Wednesday alone, according to data from Johns Hopkins University and Bloomberg. Meanwhile, hospitalizations are surging and death rates are also on the rise.


Concerns over prospects for a stimulus bill out of Washington also spooked investors. Bloomberg reported Thursday that the Trump administration was pulling back on negotiating the details of a new spending package — leaving the onus of working out a deal to congressional lawmakers including Senate Majority Leader Mitch McConnell and House Speaker Nancy Pelosi.

Despite being carried by a wave of optimism over a potential vaccine — which sparked a powerful rally earlier in the week — the convergence of bad news sent major benchmarks tumbling into the close.

The Nasdaq outperformed but was still lower intraday, after rising 2% on Wednesday as the index tried to make up some steep losses from earlier this week. Earlier, investors fled high-growth tech shares, and piled into value and cyclical stocks on hopes that a vaccine would drive a faster economic recovery and lift businesses hardest hit earlier during the pandemic.

That swift rotation, however, was likely overdone, according to some analysts.

“I would say the death of tech was excessively premature,” Brian Belski, BMO Capital Markets chief investment strategist, told Yahoo Finance.

“Coming out of a recession and really kind of questioning what growth is going to look like over the next couple of quarters, and the higher likelihood of additional lockdowns on a state or even nation-wide level, really puts that increased confidence and bid in the technology stocks,” he added. “So again, the death of technology stocks and the stay-at-home trade I think is way, way, way too early.”

The U.S. has recently faced an increasingly dire situation with COVID-19, with the number of new cases reported daily topping 100,000 each day since Nov. 4, according to data compiled by the New York Times.

The rising infection rate threatens to put the brakes on the economic recovery despite improving prospects for a vaccine, given that approval and distribution likely won’t come for another at least several more months. Pfizer (PFE) earlier this week reported early efficacy data showing their vaccine candidate was more than 90% effective in preventing COVID-19, and Moderna (MRNA) said it was closing in on releasing data from its own late-stage clinical trial in the near-term.

“The virus resurgence poses a key risk to the growth outlook,” Goldman Sachs economist Jan Hatzius said in a note Wednesday, warning that new lockdowns would jeopardize growth that’s still rebounding from the restrictions seen in the spring.

“While the data also suggest that voluntary consumer behavior has responded less strongly to increased virus risks during the recent resurgence, this could change should perceived risks increase as case counts, hospitalizations, and fatalities rise,” Hatzius added.

Separately, investors digested new labor market data that, while better than expected, failed to improve market psychology. Another 709,000 Americans filed for first-time unemployment benefits last week, for a level still more than three times higher than the weekly average of new claims in 2019. And more than 21 million Americans remain on unemployment benefits of some form.

No, why do I want to create panic? I speak calmly, did I say sell all sell all run run run?

I specifically say I am not advising to sell, and remind to be careful as prospect is uncertain - did genting suddenly become super profitable?

Sure I have been investing in Topglvoe for years, but that did not take away anything from me to appreciate Genting. In fact, I never praise Topglvoe and say buy buy buy go go go. I always discuss about pros and cons, not just gogogogoggogogog

My advice posted earlier for someone who complained about Tg: 不要以基本面为理由 来说服自己其实不是在短期投机

如果你真的是看基本面 那你买了股票就应该放着不看 久久观察一次就好 公司的基本面哪里会每天上下改变？哪里有今天基本面好明天不好？如果没有改变就不用看。

最怕的是很多人明明想要炒股赚短期钱 但是过不了心理那关 所以找借口说是在买基本面 然后起不来就不开心

抱歉讲话难听了一点 但是很多散户都是乱买乱卖亏钱

最后一点建议 你真的想玩基本面 那你就准备一笔钱 当疫苗真的出来+各国宣布stimulus package 这时TG会跌到很夸张 这时候你大买一笔 越跌 越买越多 放着5年不看 那才是真正的赚大钱

不要去贪赚短期的小钱 一直进 一直出 迟早有一天算错

别人赚多少是别人的事 不去看不去比较 就不会起贪念 心要定你要做好自己的本分 脚踏实地 老老实实投资 真真正正当股东 这样5-10后 你赚的钱 肯定比那些短期进出进出炒股炒warren的”高手”玩家还要更多 而且赚多很多很多

你问我这样讲有没有依据？我只是看看身边的例子 炒股赚几百千的最后也把这些钱输掉 反而有一个家伙收QL整十年 慢慢累积到千多粒 赚得吓人 另外一个身边的人 收Kossan也近十年 收了近600粒 也赚得好几m 还有另一个朋友也是全家收Tg 数目太大无法计算 这些好公司一直成长 一直bonus

反正 在对的时机买进 收着 守着 钱就是你的

Tg是我对topglove的简称 强哥你要自己研究我不call buy和sell 不过我的分析是 亚行最近是炒股 业务水深火热 但是因为疫苗消息暴涨 要真正变成赚钱的公司还需一段时间 而且也不容易 因为受伤很重 如果买 可能可以赚快钱 不过我是不喜欢玩这种钱的 我的投资都是收好几年 稳稳在当股东 你若能找到这种公司 就买了收着 不要想着每天上 好的公司没有每天上的 但是收三年 上的程度比那些每天上的更多 而且三年下来你都安心

I'm holding TOPGLOV too but I don't advice to buy. Still waiting to dispose at a breakeven price. Upside are very limited as the recent trading pattern can tell. Company director are buying back shares to support the price but for how long can this be sustain?